Bal Pharma Ltd

BALPHARMA

Watchlist

AI Mode

‌

Market Cap

₹ 119 Cr

P/E

17.40

‌

‌
‌

‌

‌
‌

Investment Checklist

How to read checklist?

Performance

STEADY PERFORMER

Valuation

REASONABLE

Growth

STABLE

Profitability

MODERATE MARGIN

Technicals

Bearish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Bal Pharma Ltd (BPL) is part of the Mcro Laboratories Group, specializing in the manufacture and marketing of pharmaceutical formulations like paracetamol, gliclazide, etc.

The company has progressively expanded its product range and entered cardiac specialities, utilizing divisions like 'SERVETUS' for dedicated marketing.

BPL has recently launched new drug formulations like Sitagliptin and its combination with Metformin, indicating product innovation.

Historically, BPL has engaged in strategic acquisitions, such as Golden Drugs Pvt Ltd, enhancing its manufacturing capabilities and portfolio diversification.

The company's ongoing investment in an integrated API unit reflects its commitment to expanding production capacity and operational scope.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

Market Cap

119 Cr

Volatility

Low Risk

P/E Ratio

17.4

Industry P/E

30.8

PEG Ratio

—

P/B Ratio

1.5

52W High

131.45

52W Low

70.20

Sales CAGR

-10.65%

2.56%

12.13%

10Y

4.60%

Profit CAGR

-2.82%

-3.12%

—

10Y

12.03%

ROE

TTM

8.71%

8.06%

8.47%

10Y

4.14%

ROCE

TTM

8.78%

18.54%

18.90%

10Y

14.32%

Technicals

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
SOTAC	123.40	136 Cr	17.76	2.56	0.00	15.37	16.39	8.19
ACHYUT	5.68	132 Cr	280.00	4.21	0.00	1.36	1.73	1.26
BALPHARMA	71.50	119 Cr	17.40	1.52	1.61	8.71	8.78	1.97
DENISCHEM	79.30	109 Cr	15.17	1.24	1.92	8.16	14.50	5.79
VAISHALI	8.04	105 Cr	—	1.56	0.00	-0.57	1.54	-0.32
ACCPL	90.85	101 Cr	14.87	2.24	0.00	19.50	25.71	15.37
JSTL	61.99	97 Cr	—	2.06	0.00	-9.29	-5.26	-5.27

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	70	93	82	95	74	74	73	82	66	74
Expenses	64	85	74	85	68	66	65	74	60	68
Operating Profit	6.44	7.70	7.79	9.60	6.47	7.69	7.76	7.64	6.06	5.72
OPM %	9.15	8.32	9.54	10.14	8.70	10.44	10.61	9.33	9.20	7.73
Other Income	0.16	0.14	0.10	2.45	0.82	-0.20	0.51	1.08	0.72	1.12
Interest	3.64	3.82	3.66	4.14	4.24	3.65	5.01	3.95	4.05	3.86
Depreciation	2.53	2.42	2.96	2.16	2.43	2.48	2.69	2.18	2.52	2.27
Profit Before Tax	0.43	1.60	1.27	5.75	0.62	1.36	0.57	2.59	0.21	0.72
Tax %	79.07	39.38	33.07	3.83	58.06	23.53	8.77	-109.27	0.00	0.00
Net Profit	0.09	0.97	0.85	5.53	0.26	1.04	0.52	5.42	0.21	0.72
EPS in Rs	0.06	0.61	0.54	3.71	0.16	0.65	0.33	3.40	0.13	0.45

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	235	211	225	171	251	281	304	339	303	295
Expenses	214	194	208	166	226	258	279	308	274	265
Operating Profit	21	17	18	4.88	24	23	25	32	30	29
OPM %	8.88	8.07	7.78	2.85	9.76	8.35	8.26	9.29	9.75	9.90
Other Income	3.04	1.73	1.01	1.85	1.14	5.15	0.94	2.85	2.20	2.11
Interest	8.49	9.14	13	13	12	10	12	15	17	17
Depreciation	6.49	6.77	6.15	7.68	9.52	9.04	9.13	10	9.77	9.87
Profit Before Tax	2.87	2.88	-0.20	-14	4.10	9.18	4.75	9.05	5.14	4.73
Tax %	113.79	86.94	1,163.74	4.71	-14.86	37.87	44.84	17.70	-40.86	-52.01
Net Profit	-0.40	0.38	2.15	-13	4.71	5.70	2.62	7.45	7.24	7.19
EPS in Rs	-0.62	—	2.21	-7.80	3.08	3.43	1.65	4.92	4.54	4.31
Dividend Payout %	80.65	50.94	37.45	0.00	29.94	26.39	59.52	24.19	26.43	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	13	14	14	14	14	15	15	16	16	16
Reserves	42	48	51	52	38	39	44	48	53	61
Borrowings	85	89	103	116	113	105	98	131	140	150
Other Liabilities	71	82	92	79	73	82	104	118	111	108
Total Liabilities	211	233	260	261	238	240	261	313	320	336
Fixed Assets	56	60	71	70	71	69	67	76	77	87
CWIP	3.93	1.70	0.21	3.63	3.32	0.00	1.61	0.00	0.47	2.79
Investments	0.02	0.02	0.02	0.02	0.00	0.00	0.00	0.00	6.76	2.47
Other Assets	151	172	188	187	164	171	192	237	235	244
Total Assets	211	233	260	261	238	240	261	313	320	336

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	-19	6.31	0.58	7.76	23	22	27	-1.54	23	20
Cash from Investing Activity	-14	-7.96	-3.56	-8.04	-4.71	-5.53	-9.48	-22	-19	-15
Cash from Financing Activity	32	-5.94	3.53	0.01	-20	-17	-17	24	-1.21	-7.84
Net Cash Flow	-0.86	-7.58	0.55	-0.27	-1.43	0.17	0.09	0.37	2.71	-2.44

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	51.61%	51.61%	51.61%	51.61%	51.23%	51.23%	51.23%	50.86%	50.86%	50.86%	50.86%	50.86%
FIIs	0.18%	0.00%	0.17%	0.14%	0.13%	0.13%	0.13%	0.13%	0.14%	0.14%	0.15%	0.22%
DIIs	0.00%	0.17%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.00%	0.00%
Public	48.21%	48.23%	48.23%	48.25%	48.64%	48.64%	48.64%	49.01%	49.00%	49.00%	48.99%	48.92%
Total Shareholders	16,466	16,029	15,869	15,529	15,060	14,772	15,014	16,007	15,667	15,723	15,826	15,774

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Jul 28, 2023	Sandeep prakashchandra jain (...	Bulk	Sell	98.03	0.69 Cr	69,950	0.43
Jul 28, 2023	Sandeep prakashchandra jain (...	Bulk	Buy	99.16	0.96 Cr	96,847	0.60
Mar 22, 2023	Veena parakh	Bulk	Sell	70.00	0.71 Cr	1,02,000	0.64
Mar 22, 2023	Ajay parakh	Bulk	Buy	70.00	0.70 Cr	1,00,000	0.62

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q3 FY23

Investor Presentation

Q1 FY23

Investor Presentation

Q1 FY23

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Overview

Detailed Summary

Bal Pharma Ltd (BPL) is part of the Mcro Laboratories Group, specializing in the manufacture and marketing of pharmaceutical formulations like paracetamol, gliclazide, etc.

The company has progressively expanded its product range and entered cardiac specialities, utilizing divisions like 'SERVETUS' for dedicated marketing.

BPL has recently launched new drug formulations like Sitagliptin and its combination with Metformin, indicating product innovation.

Historically, BPL has engaged in strategic acquisitions, such as Golden Drugs Pvt Ltd, enhancing its manufacturing capabilities and portfolio diversification.

The company's ongoing investment in an integrated API unit reflects its commitment to expanding production capacity and operational scope.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

Market Cap

119 Cr

Volatility

Low Risk

P/E Ratio

17.4

Industry P/E

30.8

PEG Ratio

—

P/B Ratio

1.5

52W High

131.45

52W Low

70.20

Sales CAGR

-10.65%

2.56%

12.13%

10Y

4.60%

Profit CAGR

-2.82%

-3.12%

—

10Y

12.03%

ROE

TTM

8.71%

8.06%

8.47%

10Y

4.14%

ROCE

TTM

8.78%

18.54%

18.90%

10Y

14.32%

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	70	93	82	95	74	74	73	82	66	74
Expenses	64	85	74	85	68	66	65	74	60	68
Operating Profit	6.44	7.70	7.79	9.60	6.47	7.69	7.76	7.64	6.06	5.72
OPM %	9.15	8.32	9.54	10.14	8.70	10.44	10.61	9.33	9.20	7.73
Other Income	0.16	0.14	0.10	2.45	0.82	-0.20	0.51	1.08	0.72	1.12
Interest	3.64	3.82	3.66	4.14	4.24	3.65	5.01	3.95	4.05	3.86
Depreciation	2.53	2.42	2.96	2.16	2.43	2.48	2.69	2.18	2.52	2.27
Profit Before Tax	0.43	1.60	1.27	5.75	0.62	1.36	0.57	2.59	0.21	0.72
Tax %	79.07	39.38	33.07	3.83	58.06	23.53	8.77	-109.27	0.00	0.00
Net Profit	0.09	0.97	0.85	5.53	0.26	1.04	0.52	5.42	0.21	0.72
EPS in Rs	0.06	0.61	0.54	3.71	0.16	0.65	0.33	3.40	0.13	0.45

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	235	211	225	171	251	281	304	339	303	295
Expenses	214	194	208	166	226	258	279	308	274	265
Operating Profit	21	17	18	4.88	24	23	25	32	30	29
OPM %	8.88	8.07	7.78	2.85	9.76	8.35	8.26	9.29	9.75	9.90
Other Income	3.04	1.73	1.01	1.85	1.14	5.15	0.94	2.85	2.20	2.11
Interest	8.49	9.14	13	13	12	10	12	15	17	17
Depreciation	6.49	6.77	6.15	7.68	9.52	9.04	9.13	10	9.77	9.87
Profit Before Tax	2.87	2.88	-0.20	-14	4.10	9.18	4.75	9.05	5.14	4.73
Tax %	113.79	86.94	1,163.74	4.71	-14.86	37.87	44.84	17.70	-40.86	-52.01
Net Profit	-0.40	0.38	2.15	-13	4.71	5.70	2.62	7.45	7.24	7.19
EPS in Rs	-0.62	—	2.21	-7.80	3.08	3.43	1.65	4.92	4.54	4.31
Dividend Payout %	80.65	50.94	37.45	0.00	29.94	26.39	59.52	24.19	26.43	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	13	14	14	14	14	15	15	16	16	16
Reserves	42	48	51	52	38	39	44	48	53	61
Borrowings	85	89	103	116	113	105	98	131	140	150
Other Liabilities	71	82	92	79	73	82	104	118	111	108
Total Liabilities	211	233	260	261	238	240	261	313	320	336
Fixed Assets	56	60	71	70	71	69	67	76	77	87
CWIP	3.93	1.70	0.21	3.63	3.32	0.00	1.61	0.00	0.47	2.79
Investments	0.02	0.02	0.02	0.02	0.00	0.00	0.00	0.00	6.76	2.47
Other Assets	151	172	188	187	164	171	192	237	235	244
Total Assets	211	233	260	261	238	240	261	313	320	336

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	-19	6.31	0.58	7.76	23	22	27	-1.54	23	20
Cash from Investing Activity	-14	-7.96	-3.56	-8.04	-4.71	-5.53	-9.48	-22	-19	-15
Cash from Financing Activity	32	-5.94	3.53	0.01	-20	-17	-17	24	-1.21	-7.84
Net Cash Flow	-0.86	-7.58	0.55	-0.27	-1.43	0.17	0.09	0.37	2.71	-2.44

Bal Pharma Ltd

Bal Pharma Ltd

BALPHARMA

AI Mode

Investment Checklist

Investment Checklist

Overview

Sector

Industry

Market Cap

Volatility

P/E Ratio

Industry P/E

PEG Ratio

P/B Ratio

52W High

52W Low

Technicals

Oscillators

Neutral

Overall

Bearish

Moving Averages

Bearish

Overall

Bearish

Forecasts

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Projection

Actions

Announcements

Documents

AI Mode

AI Mode

Bal Pharma Ltd

BALPHARMA

AI Mode

Overview

Sector

Industry

Market Cap

Volatility

P/E Ratio

Industry P/E

PEG Ratio

P/B Ratio

52W High

52W Low

Investment Checklist

Financial Statements

AI Powered Summary

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Peers

Price Chart Comparison